Latest Articles
-
Is Pfizer Stock A Better Bet Compared To Eli Lilly?
We think that Pfizer (NYSE:PFE) currently is a better pick compared to Eli Lilly & Company (NYSE:LLY) . PFE stock trades at about 5x trailing revenues, compared to around 8x for LLY. Does this gap in Pfizer’s valuation make sense? We...
-
Should You Buy Pfizer For 25% Gains?
[Updated: 5/6/2021] 25% Upside For PFE Stock The stock price of Pfizer (NYSE:PFE) has seen a 7.5% rise over the last ten trading days, and we believe that the stock may continue to trend higher after the company announced solid Q1 results. Pfiz...
-
All Eyes On Covid-19 Vaccine Contribution As Pfizer Reports Its Q1
Pfizer (NYSE: PFE) is scheduled to report its Q1 2021 results on Tuesday, May 4. We expect the company to likely post revenue and earnings above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overall pickup i...
-
Pfizer Covid-19 Vaccine Updates: Booster Shots, E.U. Supplies
Pfizer (NYSE: PFE) and its German partner BioNTech currently produce one of the most sought-after Covid-19 vaccines. Below are some of the recent updates relating to the shot. Firstly, Pfizer CEO Albert Bourla has said that people who receive Co...
-
New Developments For Covid-19 Shot Bode Well For Pfizer Stock
Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 shot has emerged as one of the most sought-after vaccines. Below are some of the recent updates relating to the shot. Pfizer recently indicated that its vaccine was over 91% eff...
-
Will AstraZeneca’s Covid-19 Troubles Help Pfizer Stock?
AstraZeneca’s (LON: AZN) Covid-19 vaccine was seen as key to fighting the pandemic globally, given its low cost and easy distribution, but its roll-out and uptake haven’t exactly been smooth. The shot was recently suspended from use i...
-
Pfizer Covid-19 Vaccine Updates: Will Demand Cool In 2022, Despite Growing Capacity?
Pfizer (NYSE: PFE) and its German partner BioNTech have indicated that they should have the capacity to produce as many as three billion doses of their Covid-19 vaccine in 2022, subject to demand. For perspective, Pfizer intends to produce about ...
-
Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain
Last week, there were two positive developments relating to Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can to...
-
Forecast of the Day: Pfizer’s Immunology Drugs Revenue
FDA has accepted to review Pfizer’s (NYSE: PFE) 20-valent pneumococcal conjugate vaccine for the prevention against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, in adults ages 18 years and older....
-
Buy Pfizer Stock Or JNJ For Vaccine Run?
While Merck looks like the best pick among the three pharma giants, what if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S...
-
What The Approval Of The Covid Vaccine In The U.K Means For Pfizer Stock
Pfizer ‘s (NYSE: PFE) Covid-19 vaccine has been approved for emergency use in the United Kingdom, with initial shots likely to be given as soon as next week. The U.K is the first western country to ratify the shot and the country is expecte...
-
Here’s Why Pfizer Stock Looks Inviting At $39 Levels
Pfizer’s stock (NYSE: PFE) is up just 3% since the start of the year and it has gained around 45% from its March lows. Despite the recent rally, Pfizer could offer an upside in the near term, as the company’s revenues and earnings are expec...
-
Forecast of the Day: Pfizer’s Immunology Drugs Revenue
The first interim efficacy analysis of Phase 2/3 clinical trial evaluating Pfizer and BioNTech’s Covid-19 vaccine candidate showed it to be more than 90% effective seven days after the second dose in preventing infection in participants wit...
-
Why Pfizer’s Covid-19 Vaccine Is Unlikely To Move The Needle For The Stock
Pfizer (NYSE: PFE) and its German partner BioNTech indicated that their Coronavirus vaccine, dubbed BNT162b2, was over 90% effective at preventing Covid-19 infections among volunteers, based on early data from phase 3 trials. The results are surp...
-
Pfizer, Moderna, J&J: How Are Covid Vaccine Stocks Faring?
The odds of getting a Covid-19 vaccine in the near future are improving, with major companies carrying out late-stage clinical trials. Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S. based pharma and bi...
